Metabolomics Identifies a Panel of Diagnostic Biomarkers for Early Human Embryonic Development Arrest

J Proteome Res. 2023 Apr 7;22(4):1280-1286. doi: 10.1021/acs.jproteome.2c00816. Epub 2023 Mar 28.

Abstract

Early embryonic development arrest (EEDA) is a unique form of early spontaneous abortion in pregnant women, which is previously suggested to be associated with metabolic abnormalities. Noninvasive biomarkers would significantly improve its diagnosis and clinical outcome. Here, we performed a targeted metabolomics study in plasma from EEDA patients (n = 27) and normal pregnant women (NPW, n = 27) using liquid chromatography coupled with mass spectrometry (LC-MS) to identify potential diagnostic marker metabolites. Our results showed significantly different plasma metabolic profiles between EEDA patients and NPW. Particularly, EEDA patients showed significant alterations in amino acid, carbohydrate, and vitamin metabolism, which were characterized by 21 significantly increased metabolites and five decreased metabolites in plasma. Further receiver operating characteristic analysis showed that an optimal combination of S-methyl-5'-thioadenosine, kynurenine, leucine, and malate could be used as a panel of metabolites for EEDA diagnosis. The area under the curve of the metabolite panel was 0.941, suggesting a better performance than any single metabolite for the diagnosis of EEDA. In summary, our study identifies a panel of differential metabolites in plasma that could act as potential biomarkers for the diagnosis of EEDA in clinical settings.

Keywords: diagnosis; early embryo development arrest; potential biomarkers; targeted metabolomics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Chromatography, Liquid
  • Embryonic Development
  • Female
  • Humans
  • Metabolome*
  • Metabolomics* / methods
  • Pregnancy

Substances

  • Biomarkers